79 Regarding the oral phosphodiesterase 4 inhibitor, apremilast, the mean change from baseline severity score resulted in a superior effect as compared with treatment with placebo; however, the difference did not reach statistical significance at week 24. 80 Conclusion Along with recent progress in our understanding of the pathogenesis of PsA and entry of effective new therapies into clinical settings, we can more reliably make correct diagnoses and initiate early therapeutic interventions.
1
—
—